The Beast of the East
And the West, the North and the South, apparently. It's got legs and it looks strong. Lots of folks out there are looking at this company with fresh eyes, I'd say. And it has the market cornered on bioinformatics suites when it comes to the fight against several serious medical conditions and diseases.
As word gets around about that, I think you'll see more capital investment and more than a few investors looking for a quick score come in from the cold. Investors will be looking for a place to park some funds and make money in the long term while we'll see, at least for this week, more than a few looking to make a play based on this stock's strong performance from last week and carrying into this one, so far.
Those quick strike folks may play a little havoc on end-of-day activities (what's the trading volume like right now?), but I don't think the stock will be going anywhere on a big negative slide anytime soon.